Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-016-0006-3
Title: Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy
Authors: Vo, J.H
Nei, W.L
Hu, M
Phyo, W.M
Wang, F
Fong, K.W
Tan, T 
Soong, Y.L 
Cheah, S.L
Sommat, K
Low, H
Ling, B
Ng, J
Tan, W.L
Chan, K.S 
Oon, L 
Ying, J.Y 
Tan, M.-H 
Keywords: EBV-encoded nuclear antigen 1
Epstein Barr virus antigen
virus DNA
adult
aged
blood
carcinoma
comparative study
Epstein Barr virus
female
genetics
human
immunology
male
middle aged
nasopharynx tumor
pathology
treatment outcome
tumor embolism
very elderly
virology
young adult
Adult
Aged
Aged, 80 and over
Carcinoma
DNA, Viral
Epstein-Barr Virus Nuclear Antigens
Female
Herpesvirus 4, Human
Humans
Male
Middle Aged
Nasopharyngeal Neoplasms
Neoplastic Cells, Circulating
Treatment Outcome
Young Adult
Issue Date: 2016
Publisher: Nature Publishing Group
Citation: Vo, J.H, Nei, W.L, Hu, M, Phyo, W.M, Wang, F, Fong, K.W, Tan, T, Soong, Y.L, Cheah, S.L, Sommat, K, Low, H, Ling, B, Ng, J, Tan, W.L, Chan, K.S, Oon, L, Ying, J.Y, Tan, M.-H (2016). Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy. Scientific Reports 6 (1) : 13. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-016-0006-3
Rights: Attribution 4.0 International
Abstract: Quantification of Epstein-Barr virus (EBV) cell-free DNA (cfDNA) is commonly used in clinical settings as a circulating biomarker in nasopharyngeal carcinoma (NPC), but there has been no comparison with circulating tumour cells (CTCs). Our study aims to compare the performance of CTC enumeration against EBV cfDNA quantitation through digital PCR (dPCR) and quantitative PCR. 74 plasma samples from 46 NPC patients at baseline and one month after radiotherapy with or without concurrent chemotherapy were analysed. CTCs were captured by microsieve technology and enumerated, while three different methods of EBV cfDNA quantification were applied, including an in-house qPCR assay for BamHI-W fragment, a CE-IVD qPCR assay (Sentosa ®) and a dPCR (Clarity™) assay for Epstein-Barr nuclear antigen 1 (EBNA1). EBV cfDNA quantitation by all workflows showed stronger correlation with clinical stage, radiological response and overall survival in comparison with CTC enumeration. The highest detection rate of EBV cfDNA in pre-Treatment samples was seen with the BamHI-W qPCR assay (89%), followed by EBNA1-dPCR (85%) and EBNA1-qPCR (67%) assays. Overall, we show that EBV cfDNA outperforms CTC enumeration in correlation with clinical outcomes of NPC patients undergoing treatment. Techniques such as dPCR and target selection of BamHI-W may improve sensitivity for EBV cfDNA detection. © 2017 The Author(s).
Source Title: Scientific Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/179780
ISSN: 2045-2322
DOI: 10.1038/s41598-016-0006-3
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-016-0006-3.pdf1.31 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

23
checked on Jun 15, 2021

Page view(s)

58
checked on Jun 11, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons